-
2
-
-
41149121406
-
-
Romanelli N., Gratteri P., Guandalini L., Martini E., and Bonaccini C. ChemMedChem 2 (2007) 746
-
(2007)
ChemMedChem
, vol.2
, pp. 746
-
-
Romanelli, N.1
Gratteri, P.2
Guandalini, L.3
Martini, E.4
Bonaccini, C.5
-
6
-
-
3042776739
-
-
Gatto G.J., Bohme G.A., Caldwell W.S., Letchworth S.R., Traina V.M., Obinu M.C., Laville M., Reibaud M., Pradier L., Dunbar G., and Bencherif M. CNS Drug Rev. 10 (2004) 147
-
(2004)
CNS Drug Rev.
, vol.10
, pp. 147
-
-
Gatto, G.J.1
Bohme, G.A.2
Caldwell, W.S.3
Letchworth, S.R.4
Traina, V.M.5
Obinu, M.C.6
Laville, M.7
Reibaud, M.8
Pradier, L.9
Dunbar, G.10
Bencherif, M.11
-
7
-
-
0028883258
-
-
de Fiebre C.M., Meyer E.M., Henry J.C., Muraskin S.I., Kem W.R., and Papke R.L. Mol. Pharmacol. 47 (1995) 164
-
(1995)
Mol. Pharmacol.
, vol.47
, pp. 164
-
-
de Fiebre, C.M.1
Meyer, E.M.2
Henry, J.C.3
Muraskin, S.I.4
Kem, W.R.5
Papke, R.L.6
-
8
-
-
0038210322
-
-
Astles P.C., Baker S.R., Boot J.R., Broad L.M., Dell C.P., and Keenan M. Curr. Drug Targets CNS Neurol. Disord. 1 (2002) 337
-
(2002)
Curr. Drug Targets CNS Neurol. Disord.
, vol.1
, pp. 337
-
-
Astles, P.C.1
Baker, S.R.2
Boot, J.R.3
Broad, L.M.4
Dell, C.P.5
Keenan, M.6
-
9
-
-
0038690569
-
-
Kitagawa H., Takenouchi T., Azuma R., Wesnes K.A., Kramer W.G., Clody D.E., and Burnett A.L. Neuropsychopharmacology 28 (2003) 542
-
(2003)
Neuropsychopharmacology
, vol.28
, pp. 542
-
-
Kitagawa, H.1
Takenouchi, T.2
Azuma, R.3
Wesnes, K.A.4
Kramer, W.G.5
Clody, D.E.6
Burnett, A.L.7
-
10
-
-
40749101238
-
-
Goldstein, S.; Guillonneau, C.; Charton, Y.; Lockhart, B.; Lestage, P. Eur. Patent 117081 A1, 2002; Chem. Abstr. 2002, 136, 86 625.
-
Goldstein, S.; Guillonneau, C.; Charton, Y.; Lockhart, B.; Lestage, P. Eur. Patent 117081 A1, 2002; Chem. Abstr. 2002, 136, 86 625.
-
-
-
-
11
-
-
40749155213
-
-
Lockhart B., Bonhomme N., Lebrun C., Roger A., Guillonneau C., Charton Y., Goldstein S., and Lestage P. Pharmacologist 44 (2002) A97
-
(2002)
Pharmacologist
, vol.44
-
-
Lockhart, B.1
Bonhomme, N.2
Lebrun, C.3
Roger, A.4
Guillonneau, C.5
Charton, Y.6
Goldstein, S.7
Lestage, P.8
-
12
-
-
40749087867
-
-
note
-
+), 8.25 (d, J = 2 Hz, 1H), 8.00 (d, J = 2 Hz, 1H), 4.35 (s, 2H), 2.65 (s, 3H), 1.3-0.95 (m, 4H).
-
-
-
-
13
-
-
0022379073
-
-
125I]α-bungarotoxine (2 nM) for 5 h at 37 °C. Non-specific binding was determined by incubation of membrane preparations with 1 μM α-bungarotoxine
-
125I]α-bungarotoxine (2 nM) for 5 h at 37 °C. Non-specific binding was determined by incubation of membrane preparations with 1 μM α-bungarotoxine. Marks M.J., Stitzel J.A., and Collins A.C. Pharmacol. Exp. Ther. 235 (1985) 619
-
(1985)
Pharmacol. Exp. Ther.
, vol.235
, pp. 619
-
-
Marks, M.J.1
Stitzel, J.A.2
Collins, A.C.3
-
14
-
-
0025924689
-
-
3H]cytisine for 2 h at room temperature. Non-specific binding was assessed by the incubation of membrane preparations with 10 μM S(-) nicotine
-
3H]cytisine for 2 h at room temperature. Non-specific binding was assessed by the incubation of membrane preparations with 10 μM S(-) nicotine. Pabreza L.A., Dhawan S., and Kellar K. Mol. Pharmacol. 39 (1990) 9
-
(1990)
Mol. Pharmacol.
, vol.39
, pp. 9
-
-
Pabreza, L.A.1
Dhawan, S.2
Kellar, K.3
-
15
-
-
0034745217
-
-
3H]oxotremorine (2 nM) for 2 h at room temperature non-specific binding being determined by incubation of membrane preparations with 1 μM atropine
-
3H]oxotremorine (2 nM) for 2 h at room temperature non-specific binding being determined by incubation of membrane preparations with 1 μM atropine. Lockhart B., Closier M., Howard K., Stewart C., and Lestage P. Naunyn Schmiedeberg Arch. Pharmacol. 363 (2001) 429
-
(2001)
Naunyn Schmiedeberg Arch. Pharmacol.
, vol.363
, pp. 429
-
-
Lockhart, B.1
Closier, M.2
Howard, K.3
Stewart, C.4
Lestage, P.5
-
16
-
-
40749139660
-
-
note
-
2 1.2, adjusted at pH 7.4 with 2 mM phosphate buffer). Two hours after probe implantation (stabilization period) in the rat prefrontal cortex, dialysates were collected every 30 min and analyzed by HPLC coupled to electrochemical detection. The first four dialysates were considered as baseline. Drug administration began at the end of the baseline. Data are expressed in percentage of the mean value of the baseline samples.
-
-
-
-
17
-
-
40749107645
-
-
note
-
Social recognition: Adult male Wistar rats placed in their standard home cages were exposed twice to a juvenile rat (25-30 days old) in two 5 min sessions separated by a retention interval of 120 min. Manual chronometric evaluation of exploration times (s) of the juvenile rats was performed through a video-camera system. Decrease of the exploration time toward the juvenile rate on the 2nd session indicated that the adult rat recognized the juvenile (increase of memory retention).
-
-
-
|